Strong 2024 performance and a positive outlook for 2025
London, 26 February 2025 – Hikma Pharmaceuticals PLC (‘Hikma’ or ‘Group’), the multinational pharmaceutical company, today reports its audited results for the year ended 31 December 2024.
Riad Mishlawi, Chief Executive Officer of Hikma, said:
“It’s been another strong year for Hikma with double digit revenue growth, increased profits and a resilient margin. We continued to invest in the business to support our future progress, with a strategic acquisition alongside new partnerships and agreements. This momentum combined with our diversified portfolio, leading market positions and increasing investment in R&D, underpin our positive outlook for 2025 and confidence in the future.”
|
Reported results (statutory) |
2024 $ million |
2023 $ million |
Change |
Constant currency[1] change |
|
Revenue |
3,127 |
2,875 |
9% |
9% |
|
Operating profit |
612 |
367 |
67% |
71% |
|
Profit attributable to shareholders |
359 |
190 |
89% |
98% |
|
Cashflow from operating activities |
564 |
608 |
(7)% |
- |
|
Basic earnings per share (cents) |
162 |
86 |
88% |
98% |
|
Total dividend per share (cents) |
80 |
72 |
11% |
- |
|
Core results[2] (underlying) |
2024 $ million |
2023 $ million |
Change |
Constant currency1 change |
|
Core revenue |
3,156 |
2,875 |
10% |
10% |
|
Core operating profit |
719 |
707 |
2% |
4% |
|
Core EBITDA2 |
824 |
810 |
2% |
4% |
|
Core profit attributable to shareholders |
495 |
492 |
1% |
5% |
|
Core basic earnings per share (cents) |
224 |
223 |
0% |
4% |
[1] Constant currency numbers in 2024 represent reported 2024 numbers translated using 2023 exchange rates, excluding price increases in the business resulting from the devaluation of currencies
[2] Core results throughout the document are presented to show the underlying performance of the Group, excluding exceptional items and other adjustments set out in Note 5 of this release. Core results are a non-IFRS measure. See page 14 for a reconciliation to reported IFRS results